Stability indicating HPLC method for the simultaneous determination of moxifloxacin and prednisolone in pharmaceutical formulations

Table 3 Intra-Day and Inter-Day precision of the proposed HPLC method

Drugs	Actual concentration(μg mL^-1)	Intra-day precision	Inter-day precision
Drugs	Actual concentration(μg mL^-1)	Measured concentrations; RSD (%)	Measured concentrations; RSD (%)
Moxifloxacin	25.0	24.8 ± 0.6; 1.7	25.3 ± 0.4; 1.1
	50.0	50.5 ± 0.7; 0.2	51.2 ± 0.8; 1.0
	75.0	74.1 ± 0.4; 1.5	75.7 ± 1.2; 1.5
Prednisolone	50.0	50.0 ± 0.1; 0.3	50.4 ± 1.7; 1.0
Prednisolone	100.0	101.5 ± 0.4; 0.9	102.0 ± 0.9; 0.5
	150.0	153.1 ± 0.8; 1.7	151.8 ± 0.7; 1.6

n = Average of 5 analysis, Chromatographic conditions: mobile phase methanol: 18 mM phosphate buffer 62:38, v/v, pH 2.8, Column BDS Hypersil C8 (250 X 4.6, 5 μm), flow rate 1.5 mL min^-1, injection volume 20 μL, wavelength 254 nm.

ISSN: 2661-801X